Improved survival with vemurafenib in melanoma with BRAF V600E mutation Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Dacarbazine
  • Indoles
  • Melanoma
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides

abstract

  • Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).

publication date

  • June 30, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3549296

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1103782

PubMed ID

  • 21639808

Additional Document Info

start page

  • 2507

end page

  • 16

volume

  • 364

number

  • 26